Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b cli… Read more
Oculis Holding AG (OCS) - Net Assets
Latest net assets as of : Ikr- ISK
Based on the latest financial reports, Oculis Holding AG (OCS) has net assets worth Ikr- ISK as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Ikr-) and total liabilities (Ikr-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Ikr- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Oculis Holding AG - Net Assets Trend (None–None)
This chart illustrates how Oculis Holding AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oculis Holding AG (None–None)
The table below shows the annual net assets of Oculis Holding AG from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Oculis Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Oculis Holding AG Competitors by Market Cap
The table below lists competitors of Oculis Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Okinawa Cellular Telephone Company
PINK:OKCTF
|
$945.49 Million |
|
Vienna Insurance Group AG
PINK:VNRGF
|
$945.82 Million |
|
Fastighets AB Balder Series B
LSE:0H2Z
|
$946.63 Million |
|
MLS Co Ltd
SHE:002745
|
$946.82 Million |
|
MicroPort Scientific Corporation
PINK:MCRPF
|
$944.57 Million |
|
SVG Optronics Co Ltd
SHE:300331
|
$944.43 Million |
|
Magellan Financial Group Limited
PINK:MGLLF
|
$944.26 Million |
|
Seers Technology
KQ:458870
|
$944.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oculis Holding AG's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Oculis Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Oculis Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Oculis Holding AG's net assets metrics with peer companies in the Biotechnology industry.
No peer company data available for comparison.